X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs PFIZER - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES PFIZER DIVIS LABORATORIES/
PFIZER
 
P/E (TTM) x 38.2 38.4 99.6% View Chart
P/BV x 6.2 5.6 109.8% View Chart
Dividend Yield % 0.7 0.6 119.8%  

Financials

 DIVIS LABORATORIES   PFIZER
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
PFIZER
Mar-18
DIVIS LABORATORIES/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,1422,365 48.3%   
Low Rs5331,625 32.8%   
Sales per share (Unadj.) Rs146.6430.3 34.1%  
Earnings per share (Unadj.) Rs33.078.7 42.0%  
Cash flow per share (Unadj.) Rs38.493.2 41.2%  
Dividends per share (Unadj.) Rs10.0020.00 50.0%  
Dividend yield (eoy) %1.21.0 119.1%  
Book value per share (Unadj.) Rs222.8586.5 38.0%  
Shares outstanding (eoy) m265.4745.75 580.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.74.6 123.2%   
Avg P/E ratio x25.325.3 100.0%  
P/CF ratio (eoy) x21.821.4 101.9%  
Price / Book Value ratio x3.83.4 110.5%  
Dividend payout %30.325.4 119.1%   
Avg Mkt Cap Rs m222,31891,271 243.6%   
No. of employees `00010.82.6 409.2%   
Total wages/salary Rs m4,5613,143 145.1%   
Avg. sales/employee Rs Th3,616.07,484.8 48.3%   
Avg. wages/employee Rs Th423.81,195.0 35.5%   
Avg. net profit/employee Rs Th814.91,369.1 59.5%   
INCOME DATA
Net Sales Rs m38,91519,685 197.7%  
Other income Rs m1,1341,143 99.3%   
Total revenues Rs m40,04920,828 192.3%   
Gross profit Rs m12,6175,003 252.2%  
Depreciation Rs m1,425663 215.1%   
Interest Rs m134 316.7%   
Profit before tax Rs m12,3135,479 224.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,5431,878 188.6%   
Profit after tax Rs m8,7703,601 243.6%  
Gross profit margin %32.425.4 127.6%  
Effective tax rate %28.834.3 83.9%   
Net profit margin %22.518.3 123.2%  
BALANCE SHEET DATA
Current assets Rs m45,35124,167 187.7%   
Current liabilities Rs m6,5079,544 68.2%   
Net working cap to sales %99.874.3 134.4%  
Current ratio x7.02.5 275.2%  
Inventory Days Days12755 230.0%  
Debtors Days Days9529 331.5%  
Net fixed assets Rs m21,1609,514 222.4%   
Share capital Rs m531458 116.0%   
"Free" reserves Rs m58,62526,375 222.3%   
Net worth Rs m59,15626,832 220.5%   
Long term debt Rs m025 0.0%   
Total assets Rs m67,83236,900 183.8%  
Interest coverage x926.81,305.5 71.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.5 107.5%   
Return on assets %12.99.8 132.5%  
Return on equity %14.813.4 110.5%  
Return on capital %20.820.4 102.1%  
Exports to sales %00-   
Imports to sales %21.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,35922 144,459.8%   
Fx outflow Rs m9,0421,489 607.4%   
Net fx Rs m23,317-1,466 -1,590.2%   
CASH FLOW
From Operations Rs m7,7593,318 233.8%  
From Investments Rs m-4,783-2,383 200.7%  
From Financial Activity Rs m-3,142-1,104 284.7%  
Net Cashflow Rs m-166-169 98.5%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 11.8 7.5 157.3%  
FIIs % 19.0 4.9 387.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 23.7 72.6%  
Shareholders   31,796 85,207 37.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 18, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - IPCA LABS COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS